Solana Company — Form 8-K summary
Reporting date: September 30, 2026. This current report concerns a registered direct offering; it does not report quarterly or annual operating results.
Offering terms and financial impact
- The Company agreed to issue 4,369,356 Class A shares at $3.433 per share and warrants to purchase up to an additional 4,369,356 shares at $3.776 per share.
- Expected gross proceeds are approximately $15 million; expected net proceeds are approximately $14.3 million after placement agent fees and other offering expenses.
- Clear Street is the exclusive placement agent on a reasonable-best-efforts basis and is entitled to a cash fee equal to 4.0% of gross proceeds, plus reimbursement of certain expenses.
- The offering was expected to close on or about October 1, 2026, subject to customary closing conditions. The filing does not establish that it had closed as of September 30.
- The warrants are exercisable upon issuance, expire 5.5 years after issuance, and include customary adjustment provisions. Exercise is subject to beneficial-ownership limits of 4.99%, or 9.99% if elected, with specified notice rights to change the limit.
Use of proceeds and outlook
The Company said it currently plans to use net proceeds to accumulate SOL, fund working capital and general corporate purposes, expand the business, and pursue other strategic initiatives. These are forward-looking plans and are subject to market conditions, execution, and other risks. The filing refers investors to risk factors in the Company’s periodic SEC reports.
Operating results and liquidity
This 8-K provides no revenue, profit, cash-flow, margin, debt, or broader liquidity figures, and no comparable-period results or operating guidance. It does not provide a clear value for the Company’s existing cash or total shares outstanding.
Key facts for investors to verify
- Whether the offering closed and the actual proceeds received after fees and expenses.
- The final share count outstanding and resulting dilution, including potential dilution if all warrants are exercised.
- The actual allocation of proceeds, including amounts used to accumulate SOL and the terms and risks of any such holdings.
- The complete purchase agreement, warrant, and placement agency agreement terms filed as exhibits.